Company intelligence / Profile preview

TRIO Pharmaceuticals

San Diego, California, USA

Ownership: Private
Development stage: Other

Overview

TRIO Pharmaceuticals develops novel dual-targeting bispecific antibodies and antibody-drug conjugates designed to both directly attack tumors and modulate the tumor microenvironment by reducing immunosuppression. Their lead technologies have shown promising preclinical activity. The company recently completed a $3.1 million financing round to advance its pipeline toward clinical trials.

Therapeutic areas: Oncology
Modalities: Bispecific antibodies (dual targeting antibody drugs)Antibody-drug conjugates (ADCs)Immunotherapeutics
Industry: Biotech

Partnerships

Ajinomoto Bio‑Pharma Services – collaboration for site-specific ADC development using AJICAP™ technology

Beyond the preview

Go deeper on TRIO Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TRIO Pharmaceuticals.

Explore the full profile